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Objective: Combined Pulmonary Fibrosis and Emphysema (CPFE) and Idiopathic 
Pulmonary Fibrosis (IPF) are separate entities characterised by distinct clinical, functional, radiological, and pathological 
characteristics. Comorbidities and complications are commonly seen in both diseases. Our purpose was to investigate which 
comorbidities are more common and what is their impact in the outcome of CPFE and IPF. The demographic and clinical data were 
also studied. Materials and Methods: This is a retrospective cohort study. We have reviewed the medical records of the patients 
diagnosed with interstitial lung diseases in University Hospital of lung diseases “Shefqet Ndroqi”, in Tirana, in the period from 
January 2012 till April 2016. The subjects (51 in total) were further divided in two groups: the patients diagnosed with CPFE (25) 
49% and the others (26) 51% with IPF. For testing the impact of comorbidities in CPFE syndrome, we have used linear regression 
with multiple factors using EViews 7 program. "The Student test" is used to evaluate the importance of comorbidities and 
complications in CPFE and IPF. The demographic and clinical data are expressed in average values using standard deviations ± 
SD. Results: All of the patients had comorbidities and complications. In CPFE syndrome predominate male smokers or ex-
smokers. UPY is higher in CPFE. The time from the appearance of symptoms to the diagnosis is longer in CPFE than in IPF 
patients. Comorbidities have more impact in CPFE syndrome (p = 0.01). In IPF we didn"t find any significant relationships in 
comorbidities, but we have to remind that the number of patients was  small. Conclusion: Comorbidities are frequent in CPFE and 
IPF patients. Some of them, especially lung cancer, influence strongly in the survival rate and some others, like respiratory 
insuficiency, may play an important role in the outcome of the disease. However, further research is needed to clarify the impact of 
comorbidities in CPFE syndrome.  
  
Introduction 
 
There is a new syndrome described recently calledCombined Pulmonary Fibrosis and 
Emphysema (CPFE), by Cottin et al.It is a distinct entity and it is characterised by the coexistence 
of theupper lobe emphysema and lower lobe fibrosis. CPFE patients are mainly male, heavy 
smokers or ex smokers. In  contrast with  their aggravated clinical condition they  have  almost  
normal or slightly reduced pulmonary  function  and  significant impairment of diffusion capacity. 
The prognosis and  the mortality are not well known yet. Actually there is no specific treatment for  
patients with  CPFE syndrome [1]. 
 
Idiopathic Pulmonary Fibrosis (IPF) is the most usual form of a large group of lung 
diseased named Interstitial Lung Diseases (ILD). Its  most frequent signs and simptoms are dry 
cough and exertional dyspnea. The lung tissue in IPF is more stiff and hence has lost the 
compliance and elasticity. There is little known for the etiology and fispathology.  
 
These patients have a  high mortality rate. Fortunately for the treatment of IPF there are 
some new  medications  approved  lately [2, 3, 5]. CPFE and IPF may be associated with a large 
number of comorbiditiesand complications [4-6].  
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In our study, we intended to explorethe presence ofcomorbidities and complications in a 
group of 51 patients; to assesswhich are the most commonand how important they are in CPFE 
and IPF outcomes. We collected alsoinformation fromthe baseline demographics, including age, 
gender, smoking habits (pack per year), pulmonary function tests and diagnostic procedures.  
 
All results were discussed in a multidisciplinary board, consisting of clinical, radiological 
and  pathological experts in the field.  
Materials and Methods 
The research  protocol  was  approved  by  Ethics  Committees  the  University  of  Tirana  
and   the  University  Hospital  “Shefqet Ndroqi” Tirana,  Albania; the institutions  in which the  
work was  undertaken. 
 
Patient Selection 
 
51 patients (pts)in total with Interstitial Lung Diseases (ILD) were included in the study. 
 
Inclusion Criteria 
 
IPF patients were diagnosed with the HRCTscan imaging patterns according to the new 
ATS/ERScriteria [2,3]. CPFE  pts  were  identified   based   to  the  following  features  prescribed  
by  Cotin et al  on  CT  findings [1]. 
 
 The presence of bilateral emphysema and/or multiple bullae (>1 cm) with upper zone 
predominance 
 The presence of bilateral significant pulmonary fibrosis, with peripheral and basal 
predominance 
 
Exclusion Criteria 
 
Patients were  not  included  in   this  study  if  they  exhibited any of the following criteria: 
 Who haddrug-associated ILD 
 Who  had  occupationally related ILD, such as asbestosis and silicosis 
 
In total26 (51%) diagnosed with IPF and 25 (49%) with CPFE. There were 10 (38. 4%) 
male and 15 (57.6%) female in IPF and in CPFE group ofpts 16 (64%) males and 14 (36%) 
females. Mean age for CPFE was 68±7 and for IPF patients 68±8. All patients were current 
smokers or ex-smokers. Smoking status for every patients was estimated using the Unit Pack 
Year(UPY).  
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Statistical Analysis 
 
All data recorded in the study were analyzed using EViews-7 program, a softwarethat 
processes econometricvariousstatisticaldifference for testing any hypothesis. Average values and 
standard deviations ± SD for the demographic data were collected. For determining the 
relationship between comorbidities in CPFE and IPF we  have used the  analysis  of  the logistic 
regression. To test the impact of variables in CPFE syndrome we have used linear regression with 
multiple factors. As influential variables are taken comorbidities and complications. For testing 
the importance ofthem in CPFE and IPF is used “The Student test” (t). R-square is used 
todetermine theimportanceof themodel. As statistically significant, values of p < 0.05 were 
accepted. 
 
Results 
 
In our group we had in total 51 subjects with ILD. 26 (51%) with IPF and 25 (49%) with 
CPFE.The subdivision of male/female ratio in CPFE was 16 (64%) males and 9 (36 %) females, in 
IPF 10 (38. 5%) males and 16 (61.5%) females.As noted in CPFE predominates males, meanwhile 
in IPFfemalesaremore,considering that all pts weresmokers or heavy ex smokers. Almost always 
different studies have shown that  more men have been diagnosed with IPF than women, but IPF 
in women appears to be on the rise [15]. Mean age for CPFE was 68 ± 7 and for IPF patients 68 ± 
8. Tab1 shows some demographic and clinical data as: age, gender,the time of symptoms since 
diagnosisand smoking history usingUPY. It is clearly visible that the age of the pts for both groups 
are nearly the same.  
Table 1: Demographic and Clinical Data 
 CPFE(N=25) IPF(N=26) 
Sex,m/f
20
% 16 (64%)/9 (36%) 10 (38.5%)/16 (61.5%) 
Age,years, mean ± SD
21
 68 ± 7 68 ± 8 
UPY
22
,mean ± SD 45 ± 7 36.15 ± 10 
Symptoms, months,mean± SD 27.07 ± 5 27.8±8 
 
Patients with CPFE had higher values of UPY compared to the other group. This supports 
the fact that pts with this syndrome are heavier smokers and their clinical characteristics and 
outcomes are poorer than those with IPF only [14].  
 
 
 
                                                          
20Male/female 
21Standard deviation 
22 Unit pack year 
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Figure 1: Unit Pack Year (UPY), CPFE vs IPF 
In graph 1 we compared UPY values in months for both diseasesand the difference 
between them is evident. Smoking is the main risk factor inpatients with IPFandin some 
otherswith CPFEsyndrome [9,14]. The time of symptomshad differences too among both 
groups.We think that this might be due to underdiagnosing ofCPFEas a resultof itslack of 
significant changes in pulmonary volumes in spirometry.  
                     
                         Figure 2: Symptoms in CPFE         Figure 3: Symptoms in IPF 
 
Patients with CPFE syndrome tend tohave longer time with symptoms compared to those 
with IPF.  
 Page | 47  
Anglisticum Journal (IJLLIS), Volume: 6| Issue: 3 |  
March  2017  e-ISSN: 1857-8187   p-ISSN: 1857-8179                                                                                         
The comorbidities and complicationsthat we found more commonly in the medical 
recordsin both diseases are as listed: Pulmonary Hypertension, Respiratory Failure, Lung Cancer, 
Pulmonary Embolism, Arterial Hypertension, Cardiac diseases, Anaemia, Gastritis, Rheumatic 
diseases, Diabetes Mellitus. Tab 2 analyses and interprets comorbidities and complications in 
patients with IPF. Ift values > 2, a variable is statistically important. P value express the error 
margin. If p<0.05 with 5% of error margin, this means that statistically these values are correct.  
 
If  p>0.05, the results may be changed then. As it is noticed in the tab 2, nearly all 
comorbidities and complications have p>0.05, t<2 in all of them and r = - 0.01. These statistical 
findings of our study explain that none of the comorbidities is so important to affect the outcome 
of the diseases in our group, but the small number of subjects participating in the survey should be 
noted. 
 
Table 2: Comorbiditiesand complications inIPF 
 Coefficient Std. Error t-Statistic Prob. 
Anaemia 0. 235333 0. 336809 0. 698713 0. 4887 
L. Ca
23 
-0. 108913 0. 288217 -0. 377884 0. 7075 
DM
24 
0. 052993 0. 296853 0. 178516 0. 8592 
Gastritis 0. 048979 0. 200653 0. 244100 0. 8084 
HTA
25 
0. 566592 0. 143710 3. 942614 0. 0003 
HTP
26 
0. 068783 0. 223648 0. 307551 0. 7600 
CD
27 
-0. 225784 0. 321192 -0. 702958 0. 4861 
RF
28 
-0. 060192 0. 182060 -0. 330618 0. 7426 
Rh. Diseases
29 
-0. 413312 0. 306065 -1. 350405 0. 1843 
PE
30 
-0. 104099 0. 386508 -0. 269331 0. 7890 
R-squared -0. 019869 
 
Tab 3 shows comorbidities and complications in CPFE syndrome. Some ofthem havep 
value ˃ 0.05 such as RF (p=0.01, t=2.6), Rh.d (p=0.008, t=2.7). These two factors,rheumatic 
diseases and respiratory failure are statistically more important in CPFE syndrome. 
 
In some of the connective tissue diseases, especially rheumatoid arthritis and systemic 
sclerosis, CPFE syndrome may be present too and it is defined as „idiopathic‟ (tobacco-related) 
CPFE [16].  
                                                          
23 Lung Cancer 
24Diabetes Mellitus 
25 Arterial Hypertension 
26Pulmonary Hypertension 
27Cardiac Diseases 
28Respiratory Failure 
29Rheumatic Diseases 
30Pulmonary Emboli 
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Another factor that plays an important role in the exacerbation of CPFE is respiratory 
failure [7]. If we analyze the results for lung cancer, interestingly pand t values tend to go 
respectivelyp=0.1andt=1.5.  
Table 3: Comorbidities and complications in CPFE syndrome 
 Coefficient Std. Error t-Statistic Prob. 
Anemia -0. 200062 0. 313296 -0. 638572 0. 5267 
L. Ca
31 
0. 419345 0. 268096 1. 564158 0. 1255 
DM
32 
-0. 236357 0. 276129 -0. 855966 0. 3970 
Gastritis 0. 254718 0. 186645 1. 364720 0. 1798 
HTA
33 
0. 095510 0. 133677 0. 714483 0. 4790 
HTP
34 
0. 101406 0. 208035 0. 487447 0. 6285 
CD
35 
0. 056605 0. 298769 0. 189460 0. 8507 
RF
36 
0. 451897 0. 169351 2. 668408 0. 0109 
Rh. Diseases
37 
0. 792904 0. 284698 2. 785069 0. 0081 
PE
38 
-0. 266165 0. 359525 -0. 740324 0. 4633 
R-squared 0. 117557 
 
There are several papers that had investigated the prevalence of CPFE in patients with lung 
cancer more than fibrosis and they have concluded too that CPFE patients had a poor prognosis 
[8,11,12]. 
 
The variables (comorbidities and complications) studied in regression, according to the r-
square values in tab 3, explain 11% ofthe factors affectingthe results in CPFE syndrome. 
 
Table 4: The distribution of comorbidities and complications 
 HTP DM Rh. D C. D R. F HTA Gastritis Anemia L. Ca PE 
CPFE 0. 38 0. 115 0. 15 0. 115 0. 615 0. 77 0. 27 0. 115 0. 15 0. 115 
IPF 0. 28 0. 16 0. 16 0. 12 0. 44 0. 8 0. 28 0. 16 0. 12 0. 08 
 
                                                          
31 Lung Cancer 
32Diabetes Mellitus 
33 Arterial Hypertension 
34Pulmonary Hypertension 
35Cardiac Diseases 
36Respiratory Failure 
37Rheumatic Diseases 
38Pulmonary Emboli 
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Figure 4: The frequencyof comorbidities and complications 
Graph 4 explains the frequency of comorbidities and complications in CPFE vs IPF. It is 
clearly seen that respiratory failure, pulmonary hypertension and lung cancer are encountered 
more often in CPFE syndrome. Gastritis and anemia arehighly prevalent in patients with 
Idiopathic Pulmonary Fibrosis. [13] 
Table 5: The correlation of some variables in CPFE 
 ANEMIA L.CA CPFE/IPF DM GASTRITIS HTA C D      RF Rh Disease PE 
Anemia  1. 000000  0. 0065 -0. 064814  0. 33766  0. 265378  0. 070627  0. 561769  0. 376051 -0. 116360  0. 443346 
L. Ca39  0. 006494  1. 0000  0. 049169  0. 50325  0. 010014  0. 070627 -0. 14564 -0. 08058 -0. 116360  0. 251730 
CPFE/IPF -0. 06481  0. 0492  1. 000000 -0. 06481 -0. 012064 -0. 13276 -0. 00716  0. 175655  0. 286065  0. 059485 
DM40  0. 337662  0. 5032 -0. 064814  1. 00000  0. 137696  0. 209165  0. 208063  0. 147734 -0. 116360  0. 251730 
Gastritis  0. 265378  0. 010 -0. 012064  0. 1377  1. 000000  0. 108921  0. 048131 -0. 12427 -0. 016022  0. 388218 
HTA41  0. 070627  0. 0706 -0. 132762  0. 20916  0. 108921  1. 000000  0. 191485 -0. 01685 -0. 024338  0. 012574 
CD42  0. 561769 -0. 1456 -0. 007161  0. 20806  0. 048131  0. 191485  1. 000000  0. 344265 -0. 106525  0. 084270 
RF43  0. 376051 -0. 0806  0. 175655  0. 14773 -0. 124274 -0. 01685  0. 344265  1. 000000 -0. 163308  0. 178730 
Rh. Diseases44 -0. 11636 -0.11636  0. 286065 -0. 11636 -0. 016022 -0. 02433 -0. 10652 -0. 16330  1. 000000  0. 149080 
PE45  0. 443346  0. 2517  0. 059485  0. 25173  0. 388218  0. 012574  0. 084270  0. 178730  0. 149080  1. 000000 
 
Tab 5 shows the correlation of some comorbidities and complications with CPFE 
syndrome. As it is noticed, rheumatic diseases, lung cancer and respiratory failure have a higher 
correlation coefficient than the others.  
 
                                                          
39 Lung Cancer 
40Diabetes Mellitus 
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Discussion 
 
CPFE syndrome is recently recognized. As described in literature, we found that  patients 
with CPFE were current heavy smokers or  ex smokers and were predominantly male. Smoking is 
charged as the main etiologic factor andin all the cohortsreported a history of smoking  is a 
permanent factor [9, 10, 14].  
 
Comorbidities and complications are often meet. They mostly contribute in  morbidity and 
mortality of these two distinct pathologies.[1] Sometimes it is not easyto distinct wich are 
comorbidities and which are complications in IPF and CPFE syndrome. In our study we did not 
find any significant correlation between comorbidities andIPF. In CPFE it is rheumatic diseases 
and respiratory failure that correlate more with it. Our survey had some limitations:the number of 
record patients was relatively low and it is a retrospective collection of data from one 
institutiononly. 
Conclusion 
 
The number of published papers about CPFE is in rising.The interes for this new 
phenotype is increasing and this is due to its particular clinical, functional, and radiological 
profile. Little is known about what role do the comorbidities and complications playin CPFE 
outcome andsurvival. However, further studies are needed to elucidate certain ambiguities inCPFE 
syndrome.  
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